masthead-news

News & Events

Categories

Reset Categories

Filter by Topics

ASCO Bristol-Myers Squibb CMDCAS Conference Call Durviz FFPE Financial Results Forums Gamidor HTG HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBLCL Cell of Origin Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq System HTGEdgeSeq Illumina ISO 13485 IVD Merck KGaA Molecular Profiling Nasdaq NGS Patents Presentation QIAGEN Reports Thermo Fisher VERI/O Laboratory Services WIN Consortium WIN Symposium
Reset Filter Reset All

HTG Molecular Diagnostics Obtains CE IVD Mark for Its HTG EdgeSeq DLBCL Cell of Origin Assay and HTG EdgeSeq System

TUCSON, Ariz., July 20, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has obtained CE-IVD marking for its HTG EdgeSeq DLBCL Cell of Origin Assay and next-generation sequencing (NGS) based HTG EdgeSeq system. There are approximately 79,000 non-Hodgkin lymphomas per year in the European Union, and as many as 40% of those are diagnosed as diffuse large B-cell lymphoma (DLBCL). The 2016 updates to the World Health Organization (WHO) guidelines for the classification of lymphoid neoplasms have been reported to require subtyping of DLBCL tumors as activated B‑cell (ABC) or germinal center B-cell (GCB).

Read More

Posted on:
 

HTG Molecular Diagnostics and Firalis Announce Agreement to Develop a Theranostic Tool to Predict Response to Anti-TNF-alpha Therapies for Rheumatoid Arthritis

TUCSON, Ariz. and HUNINGUE, France, July 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products to biopharma, to biotechnology companies, and to academia, today announced an agreement to develop a next‑generation sequencing (NGS)-based theranostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).

Read More

Posted on:
 

HTG Molecular Diagnostics Announces VERI/O Laboratory Service

TUCSON, Ariz., June 23, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced the introduction of its Tucson‑based VERI/O laboratory service, offering laboratory support for its biopharma clients in biomarker research and companion diagnostic development. The VERI/O laboratory service formalizes and expands HTG’s traditional service offerings, including molecular profiling of retrospective cohorts to support development of targeted and immuno-oncology therapies, building custom research-use-only (RUO) assays to support early stage clinical programs, and developing companion diagnostic assays for use in Phase III registration trials.

Read More

Posted on:
 

HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

TUCSON, Ariz. and LOS ANGELES, June 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3–7, 2016 in Chicago, IL.

Read More

Posted on:
 

HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb

TUCSON, Ariz., May 12, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb’s translational research activities.

Read More

Posted on:
 

HTG Molecular Diagnostics to Hold 2016 First Quarter Financial Results Conference Call on May 12, 2016

TUCSON, Ariz., May 02, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 first quarter financial results after market close on Thursday, May 12, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Thursday, May 12 to discuss these results and answer questions.

Read More

Posted on:
 

HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and Portugal

TUCSON, Ariz., April 11, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.

Read More

Posted on:
 

HTG Molecular Diagnostics Announces IVD Development and Supply Agreement with Thermo Fisher Scientific

TUCSON, Ariz., March 21, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has entered into a long-term agreement with Thermo Fisher Scientific under which HTG will have the right to develop a number of in-vitro diagnostic (IVD) tests for use with Thermo Fisher’s next-generation sequencing Ion PGM Dx System.

Read More

Posted on:

Page last updated March 20, 2023